Breaking News Instant updates and real-time market news.

SNAP

Snap

$12.08

0.55 (4.77%)

, FB

Facebook

$183.09

1.6 (0.88%)

11:59
04/23/19
04/23
11:59
04/23/19
11:59

On The Fly: What to watch in Snap earnings report

Snap Inc. (SNAP) is scheduled to report results of its first fiscal quarter after market close on April 23, with a conference call scheduled for 5:00 pm ET. What to watch for: 1. USER GROWTH: With its last report, Snap said that its Daily Average Users, or DAUs, were 186M, flat quarter-over-quarter and down 1M users from last year. At the time, CEO Evan Spiegel said, "We ended the year with user engagement stabilizing in advance of the broad rollout of our Android improvements, with overall Q4 daily active users flat quarter-over-quarter and average time spent above 30 minutes per day... We are seeing our investments in improving the Snapchat experience beginning to bear fruit on iOS. In Q4, our iOS daily active users increased both quarter-over-quarter and year-over-year, and average time spent on iOS grew faster during Q4 than it did last year. This is great progress following our redesign, and we look forward to continuing to grow engagement on our platform." On April 10, eMarketer's Ross Benes said he expects Snapchat's U.S. monthly user base to decline 2.8% this year to 77.5M, but sees Snapchat increasing its worldwide monthly user base 11.3% to 297.7M in 2019. In a statement to media outlets and BTIG's Rich Greenfield following that report, Snap called the methodology of eMarketer's forecast "flawed" and said its user forecast is more than 10M off from the company's publicly available reach on its ad buying tool. 2. RECENT SUMMIT: On April 4, Snap hosted its first-ever partner summit, which was viewed as part of an ongoing effort to be more open and communicative as the company faces competition from other platforms like Facebook's (FB) Instagram and up-and-comer TikTok. At the event, Snap announced Snap Games, a real-time multiplayer gaming platform featuring original and third-party video games from a number of developers. The company also made several other announcements, including a Bitmoji clock face partnership with Fitbit (FIT), a new slate of Snap Originals shows and new augmented reality and camera search experiences. 3. SHARE PERFORMANCE STRONG, ANALYST VIEWS MIXED: Social stocks have outperformed year-to-date, up ~55% versus the Nasdaq's rally of 20%, with Snap being the top performer with an advance of 120% after lagging the group in 2018, Jefferies analyst Brent Thill recently told investors. Thill is "incrementally positive" on Snap's "encouraging momentum," but says the company is "not out of the woods yet." If Snap can deliver on daily active user growth in Q1, it should be a catalyst for shares. However with the stock trading at nine-times 2019, these improvements are largely priced in, Thill said. On April 18, Wedbush analyst Michael Pachter downgraded Snap to Neutral from Outperform, citing valuation. Pachter expects Snap to report Q1 results modestly above guidance and consensus and foresees Q2 guidance roughly in-line with consensus, but he believes the stock's current price leaves little room for upside. He maintained a $12.25 price target on Snap shares. On April 5, RBC Capital analyst Mark Mahaney upgraded Snap to Outperform from Sector Perform and raised his price target for the shares to $17 from $10. The analyst sees early evidence that its Android platform improvements are "finally gaining traction." Snap may have reached a fundamentals inflection point, Mahaney told investors. Further, the analyst views the stock's valuation as "much-less demanding" relative to 2017, he said. This morning, Credit Suisse analyst Stephen Ju raised his price target for Snap to $13 from $10.50 and reiterated an Outperform rating, noting that the company recently released an updated version of its Android App, which he believes will place it in a better position to address user demand across the globe. Ju now expects 3M incremental users for 2019 versus a 1.5M decrease he forecast previously.

SNAP

Snap

$12.08

0.55 (4.77%)

FB

Facebook

$183.09

1.6 (0.88%)

  • 23

    Apr

  • 24

    Apr

  • 03

    Jun

SNAP Snap
$12.08

0.55 (4.77%)

04/23/19
FBCO
04/23/19
NO CHANGE
Target $13
FBCO
Outperform
Snap price target raised to $13 from $10.50 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Snap to $13 from $10.50 ahead of quarterly results. The analyst notes that the company recently released an updated version of its Android App, which will place it in a better position to address user demand across the globe. Ju now expects 3M incremental users for 2019 versus 1.5M decrease previously. He reiterates an Outperform rating on the shares based on potential for better-than-expected user growth with a revamped Android app, advertising revenue growth acceleration by the second half of the year, and Snap being a scarce asset that offers advertisers access to a coveted younger demographic.
04/22/19
JEFF
04/22/19
NO CHANGE
JEFF
Jefferies still prefers Facebook in social, calls Twitter 'reasonably valued'
Social stocks have outperformed year-to-date, up ~55% versus the Nasdaq's rally of 20%, with Snap (SNAP) being the top performer up 120% after lagging the group in 2018, Jefferies analyst Brent Thill tells investors in a research note. The analyst continues to prefer share of Facebook (FB) in social with a Buy rating and $200 price target. He sees upside in average revenue per user and operating expenditure growth. Meanwhile, Thill is "incrementally positive" on Snap's "encouraging momentum," but says the company is "not out of the woods yet." If Snap can deliver on daily active user growth in Q1 it should be a catalyst for shares, however with the stock trading at nine-times 2019, these improvements are largely priced in, Thill tells investors in a pre-earnings research note. And while the analyst remains "fundamental fans" of Twitter, he views the stock as "reasonably valued." Further, Twitter faces tough comps for international in the first half of 2019 and for the U.S. in the second half of the year, Thill points out.
04/18/19
04/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/19
VERF
04/18/19
DOWNGRADE
VERF
Sell
Snap downgraded to Negative from Mixed at Vertical Group
Vertical Group downgraded Snap to Negative citing slowing spending growth, stagnant ROI, and lower inventory.
FB Facebook
$183.09

1.6 (0.88%)

04/23/19
FBCO
04/23/19
NO CHANGE
Target $211
FBCO
Outperform
Signs of potential value creation from Facebook new products, says Credit Suisse
Credit Suisse analyst Stephen Ju continues to anticipate the real clearing data point for Facebook shares will arrive on the Q3 report, in which he expects the OpEx/CapEx outlook to signal a return to growth for free cash flow. In the meantime, ahead of Q1 results, his checks continue to suggest minimal deceleration for U.S. budgets coupled with modest headwinds in Europe. Ju also believes there are "greater signs" of potential value creation from new products. The analyst reiterates an Outperform rating on the shares, while raising his price target on the stock to $211 from $210, as he believes Facebook will be able to drive long-term revenue growth without a material lift in ad loads with, the Street models continue to underestimate the long-term monetization potential of other billion-user properties like Messenger and WhatsApp, and free cash flow growth recovery for 2020.
04/22/19
BARD
04/22/19
NO CHANGE
Target $195
BARD
Outperform
Facebook to report in-line to better-than-expected Q1, says Baird
Baird analyst Colin Sebastian expects Facebook to report in-line to better-than-expected Q1 results this week on the back of healthy advertiser demand. Sebastian tells investors in a research note that his firm's checks continue to suggest positive trends for the Facebook ecosystem, adding that Instagram is "particularly strong," despite headline concerns over platform privacy and safety. Management continues to highlight the growing contribution from new channels/formats while Messenger remains an area of increased focus, potentially a highlight at the upcoming F8 conference next week, he says. He maintains an Outperform rating and $195 price target.
04/22/19
CLVD
04/22/19
NO CHANGE
CLVD
Buy
Facebook 2019 estimates raised at Cleveland Research
Cleveland Research analyst Chandler Converse said his checks point to Q1 revenue for Facebook in-line with management's guidance for a mid-single digit deceleration in growth, but he also noted that advertisers seem incrementally more optimistic on the adoption of Stories ads. Additionally, partners appeared to slow plans to diversify budgets away from Facebook in the near-term given better ROI trends, said the analyst, who raised his 2019 estimates and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

YARIY

Yara

$0.00

(0.00%)

20:50
06/16/19
06/16
20:50
06/16/19
20:50
Downgrade
Yara rating change  »

Yara downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTVA

Corteva

$25.20

0.23 (0.92%)

20:49
06/16/19
06/16
20:49
06/16/19
20:49
Upgrade
Corteva rating change  »

Corteva upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$125.30

0.45 (0.36%)

, SNE

Sony

$51.42

1.735 (3.49%)

19:15
06/16/19
06/16
19:15
06/16/19
19:15
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

UTX

United Technologies

$125.30

0.45 (0.36%)

SNE

Sony

$51.42

1.735 (3.49%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GS

Goldman Sachs

$191.71

0.24 (0.13%)

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

BA

Boeing

$347.19

-1.54 (-0.44%)

RTN

Raytheon

$177.38

0.195 (0.11%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 23

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

GM

General Motors

$35.66

-0.36 (-1.00%)

18:49
06/16/19
06/16
18:49
06/16/19
18:49
Periodicals
GM won't deploy self-driving fleet until safer than human driver, Axios reports »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

T

AT&T

$32.36

0.06 (0.19%)

, CMCSA

Comcast

$42.31

0.62 (1.49%)

17:58
06/16/19
06/16
17:58
06/16/19
17:58
On The Fly
Box Office Battle: 'Men in Black: International' wins weekend with just $28.5M »

Sony’s (SNE) "Men in…

T

AT&T

$32.36

0.06 (0.19%)

CMCSA

Comcast

$42.31

0.62 (1.49%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.42

1.735 (3.49%)

LGF.A

Lionsgate

$12.22

-0.85 (-6.50%)

DIS

Disney

$141.64

-0.09 (-0.06%)

VIAB

Viacom

$29.38

-0.28 (-0.94%)

VIA

Viacom

$34.61

0.14 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 08

    Aug

GS

Goldman Sachs

$191.71

0.24 (0.13%)

17:43
06/16/19
06/16
17:43
06/16/19
17:43
Periodicals
Goldman Sachs combining private-investing units, WSJ reports »

Goldman Sachs is pulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

17:38
06/16/19
06/16
17:38
06/16/19
17:38
Periodicals
Deutsche Bank to set up EUR50B bad bank, Financial Times reports »

Deutsche Bank is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$87.10

(0.00%)

16:35
06/16/19
06/16
16:35
06/16/19
16:35
Periodicals
Tires blow on United jet during Newark airport landing, Reuters reports »

Tires on a United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$87.83

-0.48 (-0.54%)

16:33
06/16/19
06/16
16:33
06/16/19
16:33
Periodicals
Target registers back online after outage blamed on tech issue, Reuters says »

Target said its payment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.18

-0.54 (-1.16%)

16:30
06/16/19
06/16
16:30
06/16/19
16:30
Hot Stocks
Intel announces program for Israeli startups targeting tech inflections »

Intel announced a program…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:27
06/16/19
06/16
16:27
06/16/19
16:27
Periodicals
Boeing says will take time to rebuild customer confidence, Reuters reports »

The head of Boeing said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

GS

Goldman Sachs

$191.71

0.24 (0.13%)

16:19
06/16/19
06/16
16:19
06/16/19
16:19
Periodicals
Goldman Sachs skeptical of 'insurance' rate cuts from Fed, Reuters says »

Goldman Sachs economists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:16
06/16/19
06/16
16:16
06/16/19
16:16
Periodicals
Trials nearing for Boeing 737 Max fix, WSJ reports »

The Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.